Candel Therapeutics, Inc.
NASDAQ:CADLBiotechnology
+$0.05 today
- Market cap
- $417.33M
- Beta
- -0.48
- P/E (TTM)
- -9.2
- EPS (TTM)
- -$0.87
Volume 1.39M
Average 1.82M
CADL Operating Cash Flow
Cash generated by the company's core business operations during the period.
Candel Therapeutics, Inc.NASDAQ: CADL
Operating Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Operating cash flow growth accelerates
Q1 FY2026 operating cash flow of $18.04M (cash outflow) rose 109.3% year over year, ahead of the +75.5% change in trailing-twelve-month operating cash flow. Sequentially, it rose 70.7% from the prior quarter. Over 3 fiscal years it compounded at +6.8% a year.
Context
- Operating cash flow grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +109.3% holds above the trailing-twelve-month pace of +75.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Operating Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (38.31M) USD
- Year-over-year change
- -41.8%
| Period | Period end | Operating Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (38.31M) | -41.8% |
| FY2024 | 2024-12-31 | (27.02M) | +21.1% |
| FY2023 | 2023-12-31 | (34.24M) | -9.0% |
| FY2022 | 2022-12-31 | (31.42M) | -41.4% |
| FY2021 | 2021-12-31 | (22.22M) | — |
Operating Cash Flow vs competitors
How CADL compares with its peers on the latest reported figures
- Peers report in different currencies, so operating cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +75.5% is the 2nd highest of 9, against a peer median of -1.2%.
- Over three fiscal years its annual growth of +6.8% compares with a peer median of +14.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $278.16M USD | -2.9% | +34.2% | 128.1% | |
| LTM Sep 2026 | $189.95M USD | -41.2% | +1.1% | 50.1% | |
| LTM Mar 2026 | $110.88M USD | -3.8% | +14.7% | — | |
| LTM Mar 2026 | $94.5M USD | -17.5% | — | — | |
| LTM Mar 2026 | $69.96M USD | +0.5% | -2.3% | 44.5% | |
| LTM Mar 2026 | $53.61M USD | +71.4% | — | 23.6% | |
| LTM Mar 2026 | $47.73M USD | +75.5% | +6.8% | — | |
| LTM Mar 2026 | $32.07M USD | +157.5% | +47.8% | — | |
GNLXGenelux Corporation | LTM Mar 2026 | $25.89M USD | +16.1% | +92.0% | 323650.0% |
NBPNovaBridge Biosciences | LTM Sep 2025 | CN¥13.15M CNY | — | -73.5% | — |
| Peer median (excluding CADL) | — | -1.2% | +14.7% | 50.1% | |
Competitors are the stored peer set for CADL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (36.12M) | (18.79M) | (37.94M) | (55.18M) | (38.18M) |
| Depreciation & Amortization | 232K | 778K | 1.28M | 990K | 845K |
| Deferred Income Tax | 11.51M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 2.96M | 2.31M | 3.09M | 5.31M | 3.82M |
| Change in Working Capital | (876K) | 71K | (378K) | 346K | 2.19M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 669K | (1.21M) | 45K | (185K) | 802K |
| Other Working Capital | (1.55M) | 1.28M | (378K) | 531K | 1.39M |
| Other Non-Cash Items | 76K | (15.78M) | (301K) | 21.51M | (6.98M) |
| Operating Cash Flow | (22.22M) | (31.42M) | (34.24M) | (27.02M) | (38.31M) |
| Capital Expenditures | (1.84M) | (1.3M) | (457K) | (16K) | (587K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 27K |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 177K | 0 | 0 |
| Investing Cash Flow | (1.84M) | (1.3M) | (280K) | (16K) | (560K) |
| Debt Repayment | 0 | 19.91M | 0 | (9.17M) | 36.21M |
| Common Stock Issued | 71.34M | 0 | 0 | 101.76M | 19.89M |
| Common Stock Repurchased | 0 | 0 | (121K) | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 465K | 64K | 0 | 1.69M | 0 |
| Financing Cash Flow | 71.8M | 19.97M | (121K) | 94.28M | 56.1M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 47.75M | (12.74M) | (34.65M) | 67.24M | 17.23M |
| Free Cash Flow | (24.05M) | (32.72M) | (34.7M) | (27.04M) | (38.9M) |
Candel Therapeutics, Inc.
NASDAQ:CADL
Intrinsic Alpha fair value
Locked
Current Price
$5.32
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.